Treatment Access Solution

A collaboration with Novartis

Glivec® (imatinib)

The Max Foundation’s long-standing shared-values partnership with Novartis was first established in 2001 through the Glivec® International Patient Assistance Program, commonly known by its acronym GIPAP. GIPAP operates in specific low and middle-income countries providing access to Glivec® (imatinib) for people properly diagnosed with chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST), and orphan indications for which Glivec has been approved. Eligible patients must meet medical and socio-economic criteria.

Additionally, the partnership between The Max Foundation and Novartis has expanded to include other treatment access models beyond GIPAP, including country-specific solutions. Patients must meet the medical criteria and program guidelines.

View our global map and click on individual countries to learn where these programs are operating today. Contact us for more information about access to Glivec® (imatinib) in these countries.

Return to Treatment Access Solutions

Go on the Patient Journey

Join Tony as he shares his story of learning about his cancer, gaining access to life-saving medication, and connecting with a community of care.
Follow Tony's Journey